The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients - European Medical Journal

The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some of the difficulties with using Ki-67, a nuclear protein associated with cellular proliferation, as a predictive parameter for response to adjuvant chemotherapy in breast cancer patients.

This content is supported by Genomic Health, Inc.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given